Diagnosis and differential diagnosis of cutaneous lymphoproliferative disorders is one of the most difficult areas in dermatopathology, and biopsies are often taken to rule out a cutaneous lymphoma in patients with “unclear” or “therapy-resistant” skin lesions. Histopathological features alone often enable a given case to be classified to a diagnostic group (eg, epidermotropic lymphomas), but seldom allow a definitive diagnosis to be made. Performing several biopsies from morphologically different lesions is suggested, especially in patients with suspicion of mycosis fungoides. Immunohistochemistry is often crucial for proper classification of the cases, but in some instances is not helpful (eg, early lesions of mycosis fungoides). Although molecular techniques provide new, powerful tools for diagnosing cutaneous lymphoproliferative disorders, results of molecular methods should always be interpreted with the clinicopathological features, keeping in mind the possibility of false positivity and false negativity. In many cases, a definitive diagnosis can be made only on careful correlation of the clinical with the histopathological, immunophenotypical and molecular features.
- ALCL, anaplastic CD30-positive large-cell lymphoma
- EORTC, European Organization for Research and Treatment of Cancer
- HTLV, human T cell lymphoma or leukaemia virus
- LyP, lymphomatoid papulosis
- PCFCL, primary cutaneous follicle centre lymphoma
- PCMZL, primary cutaneous marginal zone B cell lymphoma
- PCR, polymerase chain reaction
- SPTCL, subcutaneous panniculitis-like T cell lymphoma
- TIA, T cell intracellular antigen
- TdT, terminal deoxynucleotidyl transferase
- WHO, World Health Organization
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.